Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
New data drops, trial amendments, and sudden capital raises make In8Bio’s SEC filings dense—even seasoned biotech investors can miss a key footnote hidden in a 300-page 10-K. If you have ever asked, “How do I keep up with In8Bio insider trading Form 4 transactions or trial updates disclosed at midnight?”, this page is built for you.
Stock Titan’s AI reads every line the moment an 8-K hits EDGAR, then serves plain-English highlights so you can start understanding In8Bio SEC documents with AI instead of combing through jargon. Whether it’s an In8Bio quarterly earnings report 10-Q filing breaking down R&D cash burn, an In8Bio proxy statement executive compensation outlining option grants, or an In8Bio annual report 10-K simplified to show pipeline timelines, the platform connects each disclosure to what matters for a clinical-stage oncology company.
Use our real-time alerts to monitor In8Bio Form 4 insider transactions real-time and spot patterns in In8Bio executive stock transactions Form 4. Dive into AI-tagged sections that map trial phase progress, safety data, and convertible note terms—crucial insights typically buried deep inside filings. Need context on a sudden press release? The companion 8-K is already summarized under In8Bio 8-K material events explained. From pipeline-specific risk factors to cash-runway projections, our In8Bio earnings report filing analysis turns complex disclosures into actionable knowledge so you can focus on decisions, not documents.
IN8bio, Inc. filed a Form S-3 shelf registration to offer up to $200,000,000 of securities, including common stock, preferred stock, debt securities, warrants, rights and units, to be sold from time to time at terms set in future prospectus supplements.
Sales may be made directly, through agents, or via underwriters, including at-the-market offerings, block trades, and privately negotiated transactions. Net proceeds from primary sales by the company are intended for working capital and general corporate purposes, as described in future supplements.
The company’s common stock trades on Nasdaq as “INAB.” The last reported sale price was $1.63 per share on November 5, 2025. Public float was $10.4 million as of November 7, 2025 (based on 4,218,313 non‑affiliate shares at $2.46 on October 7, 2025), and the filing notes the I.B.6 limitation that primary sales under this shelf cannot exceed one‑third of public float while it remains below $75.0 million. IN8bio is an emerging growth company and a smaller reporting company.
IN8bio (INAB) filed its Q3 2025 10‑Q, reporting smaller losses as it cut costs and refocused its pipeline. Net loss was $3.9 million for the quarter, an improvement from $7.1 million a year ago, as total operating expenses fell to $4.0 million from $7.1 million. Year-to-date net loss was $14.5 million.
Cash was $10.7 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern, noting current cash is not expected to fund operations for 12 months. During the nine months, IN8bio raised approximately $8.5 million via its ATM program and continued to manage expenses.
The company executed a 1‑for‑30 reverse stock split in June 2025. Shares outstanding were 4,589,196 at September 30, 2025, and 4,634,396 as of November 3, 2025. Pipeline updates include continued encouraging INB‑100 AML data and the previously announced suspension of INB‑400 Phase 2 enrollment to conserve cash.
IN8bio (INAB)Exhibit 99.1 and is incorporated by reference.
The disclosure is provided under Item 2.02 of an 8‑K and, along with Exhibit 99.1, is designated as “furnished,” not “filed,” under the Exchange Act. IN8bio’s common stock trades on Nasdaq under the symbol INAB.
IN8bio, Inc. (INAB) filed an 8-K announcing new preclinical data from its gamma delta T cell engager program, INB-619. The company said the data will be presented at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago.
A company press release with additional details is attached as Exhibit 99.1 and incorporated by reference. This filing does not include financial results or transaction terms; it primarily serves to notify investors of the scientific presentation and provide the related press release.
Alyeska Investment Group and related filers report beneficial ownership of warrants to purchase 89,021 shares of IN8BIO, Inc. common stock, representing 2.58% of the outstanding shares on the stated calculation basis of 3,444,234 shares. The filing shows shared voting and shared dispositive power over the 89,021 warrants, with no sole voting or dispositive power reported. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing is a joint statement by Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh, each acknowledging joint filing responsibilities.
This Amendment No. 2 to a Schedule 13G discloses that Transcend Partners Opportunity Fund I LLC beneficially owns 107,416 shares of IN8bio common stock, representing 2.6% of the class. The percentage is calculated using 4,078,139 shares outstanding as reported as of June 30, 2025. The Reporting Person reports no sole voting or sole dispositive power and instead reports shared voting and shared dispositive power over the shares. Actions regarding these shares require a majority vote of Transcend's managing members, each of whom disclaims beneficial ownership. The amendment is a disclosure of beneficial ownership rather than an indication of control.
IN8bio, Inc. Schedule 13G/A discloses that William Tai-Wei Ho beneficially owns 151,223 shares of common stock, representing 3.7% of the class on a diluted basis. The position comprises 85,112 shares held of record, 4,866 shares held by his minor children, 3,648 shares held by other relatives over which he holds an irrevocable proxy, plus 47,914 options and 9,683 warrants that are immediately or imminently exercisable.
The filing also details voting and dispositive power: 142,709 shares with sole voting and dispositive power and smaller amounts reported as shared power. This amendment updates ownership disclosure but does not show a >5% stake or an intent to control the company.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
